The cancer therapeutic based on patient’s own modified adult mesenchymal stem cells is running under the portfolio name Agenmestencel-T.
In December 2012 apceth has concluded the first round of funding through the Federal Ministry of Education and Research (BMBF) for the development of Agenmestencel-T as part of the Munich Biotech Cluster initiative m4 Personalized Medicine and Targeted Therapies.
Apceth’s total approved budget for the development of Agenmestencel-T came to €4.7m within a period of less than five years between July 2010 and March 2015.